The past decade has seen substantial advances in our understanding of the genetic factors influencing response to a variety of drugs including warfarin. Though there has been an increase in the clinical use of pharmacogenetic information to individualize treatment regimens, yet there generally has not been broad acceptance of pharmacogenetic testing. Warfarin remains the mainstay therapy for oral anticoagulation; it also remains one of the most challenging medications to manage despite over 60 years of experience with the drug. It is one of the top 10 drugs related to adverse drug events and hospitalization. Clinical management of warfarin therapy mainly is complicated by a narrow therapeutic index and high inter-and intra-individual variability in drug disposition and response. Supratherapeutic international normalized ratio (INRs) can lead to fatal hemorrhage while subtherapeutic INRs can lead to thrombosis. Growing evidence indicates that up to 60% of the individual pharmacological response to warfarin might be due to genetic variables and affected by polymorphisms in the genes mainly, vitamin K epoxide reductase complex subunit 1 (VKORC1), the target enzyme of warfarin and cytochrome P450 2C9 (CYP2C9), the main enzyme involved in warfarin metabolism. Although the genotypes of VKORC1 and CYP2C9 are clearly the most important genetic factors for warfarin response, genetic variations in other genes for instance, CYP4F2 and GGCX also show significant association with warfarin response. Non-genetic factors such as age (elderly patients), diet (vitamin K rich diet), disease states (thyroid activity, liver or renal dysfunction, fever), other drugs (e.g., amiodarone, propafnone, metronidazole, tamoxifen, etc.), life-style (alcohol intake, smoking, exercise) can also substantially modulate the response to warfarin. VKORC1 polymorphisms have been reported to be more potent modifiers of warfarin response than the CYP2C9 polymorphisms. Recent work by Rieder et al. [1] has also shown that individuals with VKORC1 A haplotype (H1 and H2) require low warfarin dose as a result of a decreased expression of messenger ribonucleic acid when compared to individuals with VKORC1 B haplotype (H7, H8 and H9).
VKORC1 polymorphisms have been reported to be more potent modifiers of warfarin response than the CYP2C9 polymorphisms. Recent work by Rieder et al. [1] has also shown that individuals with VKORC1
A haplotype (H1 and H2) require low warfarin dose as a result of a decreased expression of messenger ribonucleic acid when compared to individuals with VKORC1 B haplotype (H7, H8 and H9).
In the present issue of the journal, Kumar et al. [2] have studied genotype, allele and haplotype frequencies of VKORC1 and CYP4F2 in South Indian population. 
